Medicamen Biotech Share Price

NSE
413.8
-4.80 (1.20%)
MEDICAMEQ • 13 Jun, 2025 | 03:29 PM
BUY

1Y Annualised Return

-11.98%

3Y Annualised Return

-12.85%

The current prices are delayed, login or Open Demat Account for live prices.

Medicamen Biotech SIP Return Calculator

Over the past

1 year
3 years

Total Investment of ₹65,00,000

Would have become ₹61,24,248 (-5.78%)

Daily SIP of 25,000 would have become 61,24,248 in 1 year with a gain of -3,75,751 (-5.78%)

Medicamen Biotech Stock Performance
Today’s Low - High
410.50
419.25
410.50
419.25
52 Week Low - High
375.05
630.00
375.05
630.00

Open

415.00

Prev. Close

418.60

Total Traded Value

1.20 Cr

View details of Market Depth
Medicamen Biotech Fundamental

Market Cap (in crs)

559.81

Face Value

10

Turnover (in lacs)

120.39

Key Metrics
Qtr Change %
34.48% Fall from 52W High
-4.5
Dividend yield 1yr %
Below industry Median
0.2

Medicamen Biotech Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Medicamen Biotech Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
29.61 Cr
45.14 Cr
44.74 Cr
43.05 Cr
47.32 Cr

Medicamen Biotech Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
168.79 Cr
181.63 Cr
143.33 Cr
117.17 Cr
113.47 Cr
127.44 Cr

Medicamen Biotech Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
1.86 Cr
2.92 Cr
0.9 Cr
0.8 Cr
2.04 Cr

Medicamen Biotech Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
6.56 Cr
9.49 Cr
14.73 Cr
14.9 Cr
12.13 Cr
13.29 Cr
Medicamen Biotech Result Highlights
  • Medicamen Biotech Ltd reported a 5.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.8%.

  • Its expenses for the quarter were up by 9.2% QoQ and 30.5% YoY.

  • The net profit decreased 30.1% QoQ and decreased 45.9% YoY.

  • The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.6 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Medicamen Biotech shareholding Pattern

Promoter
43.2%
Foreign Institutions
0.1%
Domestic Institutions
0.8%
Public
56%
Promoter
43%
Foreign Institutions
0.1%
Domestic Institutions
0.9%
Public
56%
Promoter
43%
Foreign Institutions
0.1%
Domestic Institutions
1.1%
Public
55.8%
Promoter
43%
Foreign Institutions
0.1%
Domestic Institutions
1.1%
Public
55.8%
Promoter
43.2%
Foreign Institutions
0.1%
Domestic Institutions
1%
Public
55.7%
Promoter
43.2%
Foreign Institutions
0.2%
Domestic Institutions
0.7%
Public
55.9%

Medicamen Biotech Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
413.8
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
419.40
10Day EMA
422.90
12Day EMA
424.00
20Day EMA
428.00
26Day EMA
430.90
50Day EMA
441.60
100Day EMA
456.90
200Day EMA
474.40
5Day SMA
419.90
10Day SMA
424.10
20Day SMA
428.20
30Day SMA
430.90
50Day SMA
447.40
100Day SMA
461.60
150Day SMA
476.60
200Day SMA
480.90
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
19214 Rs
30477 Rs
Week Rs
22832 Rs
36304 Rs
Month Rs
18707 Rs
30640 Rs
Resistance & Support
414.17
Pivot
Resistance
First Resistance
417.83
Second Resistance
422.92
Third Resistance
426.58
Support
First Support
409.08
Second support
405.42
Third Support
400.33
Relative Strength Index
37.29
Money Flow Index
48.70
MACD
-6.87
MACD Signal
-6.43
Average True Range
16.12
Average Directional Index
6.60
Rate of Change (21)
-8.25
Rate of Change (125)
-28.82

Medicamen Biotech Latest News

03 JUN 2025 | Tuesday

Medicamen Biotech Ltd-$ - 531146 - Announcement Under Regulation 30 (LODR)- Approval Of Abbreviated New Drug Application (ANDA)

02 JUN 2025 | Monday

Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Newspaper Publication

30 MAY 2025 | Friday

Medicamen Biotech Ltd-$ - 531146 - Compliances-Reg.24(A)-Annual Secretarial Compliance

View More

Medicamen Biotech Company background

Founded in: 1993
A diversified enterprise, Medicamen Biotech Limited (MBL) is a researchled pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence in 40+ countries. Its offerings include Finished Dosage Forms (FDFs) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough Cold, Cardiovascular Central Nervous System, AntiDiabetic, Gastrointestinal, AntiAllergic among others.The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures NonBetalactum preparations including tablets, capsules, oral liquids and ointments creams.Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.During the year 200607, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.The Company launched the marketing division in Jan09, with 16 products in Delhi Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paidup Equity Shares of Rs.10/ each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) 4,20,000 in 201920. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

As of 13 Jun, 2025, MEDICAMEQ share price is ₹412.8. The stock opened at ₹415 and had closed at ₹418.6 the previous day. During today’s trading session, MEDICAMEQ share price moved between ₹410.50 and ₹419.25, with an average price for the day of ₹414.50. Over the last 52 weeks, the stock has recorded a low of ₹375.05 and a high of ₹630.00. In terms of performance, MEDICAMEQ share price has declined by 27.1% over the past six months and has declined by 11.98% over the last year.

Read More

Medicamen Biotech FAQs

Medicamen Biotech share price is ₹413.8 in NSE and ₹414 in BSE as on 13/6/2025.

Medicamen Biotech share price in the past 1-year return was -13.2. The Medicamen Biotech share hit a 1-year low of Rs. 375.05 and a 1-year high of Rs. 630.

The market cap of Medicamen Biotech is Rs. 559.81 Cr. as of 13/6/2025.

The PE ratios of Medicamen Biotech is 59.28 as of 13/6/2025.

The PB ratios of Medicamen Biotech is 2.13 as of 13/6/2025

You can easily buy Medicamen Biotech shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Medicamen Biotech stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -